

GLAXOSMITHKLINE PLC
Form 6-K
February 01, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending February 2016

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging
Managerial Responsibility or Connected Persons

In accordance with DTR 3.1.4R(1)(a) I give details of changes in the interests of the following Person Discharging Managerial Responsibilities ('PDMR'), who acquired Ordinary Shares ('Shares') in GlaxoSmithKline plc ('GSK') at a price of 1367.57 pence per Share, following the re-investment of dividends paid on 14 January 2016, on Shares held in the GSK 2009 Deferred Annual Bonus Plan Post-Tax.

| PDMR | Number of Ordinary Shares acquired under the personal contribution element of the plan | Number of Ordinary Shares acquired under the matching element of the plan (GSK contribution) |
|-------------|--|--|
| Ms C Thomas | 37.982 | 38.185 |

GSK was advised of this allocation on 28 January 2016.

V A Whyte
Company Secretary

1 February 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: February 01, 2016

By: VICTORIA WHYTE

Victoria Whyte

Authorised Signatory for and on
behalf of GlaxoSmithKline plc